Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
54
SVA Quote, Financials, Valuation and Earnings
Last price:
$6.47
Seasonality move
:
9.32%
Day range:
$6.47 - $6.47
52-week range:
$6.47 - $6.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.50x
P/B ratio:
0.62x
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$464.9M
Revenue:
$448.3M
EPS (TTM):
-$1.31
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
ANL
Adlai Nortye Ltd.
|
-- | -$1.31 | -- | -33.06% | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$126.7M | -$0.42 | 20.26% | -35.1% | $47.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ADAG
Adagene, Inc.
|
$2.03 | $9.22 | $95.6M | -- | $0.00 | 0% | 913.61x |
|
ANL
Adlai Nortye Ltd.
|
$2.04 | -- | $75.3M | -- | $0.00 | 0% | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.99 | $4.00 | $20.3M | -- | $0.00 | 0% | 0.58x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.26 | -- | $4.1M | -- | $0.00 | 0% | 1.01x |
|
ZLAB
Zai Lab Ltd.
|
$18.37 | $47.50 | $2B | -- | $0.00 | 0% | 4.46x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 6.279 | 12.91% | 11.22x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.358 | -- | 2.23x |
|
ANL
Adlai Nortye Ltd.
|
-- | -0.187 | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | -0.497 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.111 | 56.09% | 0.09x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.105 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
ANL
Adlai Nortye Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
Sinovac Biotech Ltd. vs. Competitors
-
Which has Higher Returns SVA or ADAG?
Adagene, Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of --. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About SVA or ADAG?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 354.4%. Given that Adagene, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe Adagene, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is SVA or ADAG More Risky?
Sinovac Biotech Ltd. has a beta of 0.774, which suggesting that the stock is 22.623% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SVA or ADAG?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ADAG?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. Sinovac Biotech Ltd.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 913.61x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- ADAGAdagene, Inc.913.61x -- -- --
-
Which has Higher Returns SVA or ANL?
Adlai Nortye Ltd. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of --. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Adlai Nortye Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B ANLAdlai Nortye Ltd.-- -- -- -
What do Analysts Say About SVA or ANL?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adlai Nortye Ltd. has an analysts' consensus of -- which suggests that it could grow by 341.18%. Given that Adlai Nortye Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Adlai Nortye Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 ANLAdlai Nortye Ltd.0 1 0 -
Is SVA or ANL More Risky?
Sinovac Biotech Ltd. has a beta of 0.774, which suggesting that the stock is 22.623% less volatile than S&P 500. In comparison Adlai Nortye Ltd. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SVA or ANL?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Adlai Nortye Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Adlai Nortye Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ANL?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Adlai Nortye Ltd. quarterly revenues of --. Sinovac Biotech Ltd.'s net income of -- is lower than Adlai Nortye Ltd.'s net income of --. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Adlai Nortye Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus -- for Adlai Nortye Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- ANLAdlai Nortye Ltd.-- -- -- --
-
Which has Higher Returns SVA or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of -353.92%. Sinovac Biotech Ltd.'s return on equity of -1.05% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About SVA or CASI?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 305.02%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe CASI Pharmaceuticals, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is SVA or CASI More Risky?
Sinovac Biotech Ltd. has a beta of 0.774, which suggesting that the stock is 22.623% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.505%.
-
Which is a Better Dividend Stock SVA or CASI?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or CASI?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. Sinovac Biotech Ltd.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 0.58x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- CASICASI Pharmaceuticals, Inc.0.58x -- $3.1M -$10.9M
-
Which has Higher Returns SVA or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of -86.16%. Sinovac Biotech Ltd.'s return on equity of -1.05% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About SVA or CPHI?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sinovac Biotech Ltd. has higher upside potential than China Pharma Holdings, Inc., analysts believe Sinovac Biotech Ltd. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is SVA or CPHI More Risky?
Sinovac Biotech Ltd. has a beta of 0.774, which suggesting that the stock is 22.623% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.033, suggesting its more volatile than the S&P 500 by 3.259%.
-
Which is a Better Dividend Stock SVA or CPHI?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or CPHI?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. Sinovac Biotech Ltd.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 1.01x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- CPHIChina Pharma Holdings, Inc.1.01x -- $756.2K -$651.5K
-
Which has Higher Returns SVA or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to Sinovac Biotech Ltd.'s net margin of -30.98%. Sinovac Biotech Ltd.'s return on equity of -1.05% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital SVASinovac Biotech Ltd.-- -- $11.8B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About SVA or ZLAB?
Sinovac Biotech Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $47.50 which suggests that it could grow by 158.55%. Given that Zai Lab Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe Zai Lab Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SVASinovac Biotech Ltd.0 0 0 ZLABZai Lab Ltd.9 1 0 -
Is SVA or ZLAB More Risky?
Sinovac Biotech Ltd. has a beta of 0.774, which suggesting that the stock is 22.623% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.835, suggesting its less volatile than the S&P 500 by 16.508%.
-
Which is a Better Dividend Stock SVA or ZLAB?
Sinovac Biotech Ltd. has a quarterly dividend of $55.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sinovac Biotech Ltd. pays -328.35% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SVA or ZLAB?
Sinovac Biotech Ltd. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. Sinovac Biotech Ltd.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, Sinovac Biotech Ltd.'s price-to-earnings ratio is -- while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sinovac Biotech Ltd. is 1.50x versus 4.46x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SVASinovac Biotech Ltd.1.50x -- -- -- ZLABZai Lab Ltd.4.46x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
69
INTC alert for Jan 23
Intel Corp. [INTC] is down 17.47% over the past day.
Buy
51
APGE alert for Jan 23
Apogee Therapeutics, Inc. [APGE] is down 12.25% over the past day.
Buy
70
BNR alert for Jan 23
Burning Rock Biotech Ltd. [BNR] is down 13.61% over the past day.
